• Inventors:
  • Assignees:
  • Publication Date: December 31, 1969
  • Publication Number:

Patent Citations (0)

    Publication numberPublication dateAssigneeTitle

NO-Patent Citations (0)

    Title

Cited By (49)

    Publication numberPublication dateAssigneeTitle
    US-2005136537-A1June 23, 2005President And Fellows Of Harvard College, Biomol International L.P.Compositions for manipulating the lifespan and stress response of cells and organisms
    US-2005171027-A1August 04, 2005President And Fellows Of Harvard College, The General Hospital CorporationCompositions for treating or preventing obesity and insulin resistance disorders
    US-2006014705-A1January 19, 2006Howitz Konrad T, Zipkin Robert ECompositions and methods for selectively activating human sirtuins
    US-2006025337-A1February 02, 2006President And Fellows Of Harvard CollegeSirtuin related therapeutics and diagnostics for neurodegenerative diseases
    US-2006229265-A1October 12, 2006Sirtris Pharmaceuticals, Inc.Nicotinamide riboside and analogues thereof
    US-2006276393-A1December 07, 2006Sirtris Pharmaceuticals, Inc.Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
    US-2006292099-A1December 28, 2006Michael Milburn, Westphal Christoph H, Livingston David J, Peter Elliott, Philip Lambert, Normington Karl DTreatment of eye disorders with sirtuin modulators
    US-2007014833-A1January 18, 2007Sirtris Pharmaceuticals, Inc.Treatment of eye disorders with sirtuin modulators
    US-2007149466-A1June 28, 2007Michael Milburn, Jill Milne, Johan Auwerx, Carmen Argmann, Marie Lagouge, Michelle DippMethods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
    US-2008194803-A1August 14, 2008Sinclair David A, Li-Huei Tsai, Andre FisherCognitive Performance With Sirtuin Activators
    US-2009137681-A1May 28, 2009David A Sinclair, Antonello MaiSirtuin Inhibiting Compounds
    US-2009142335-A1June 04, 2009Joslin Diabetes CenterMethods of diagnosis and treatment of metabolic disorders
    US-2009163580-A1June 25, 2009Natrol, Inc.Anti-aging composition containing resveratrol and method of administration
    US-2009215681-A1August 27, 2009Joslin Diabetes CenterMethods of Diagnosis and Treatment of Metabolic Disorders
    US-2009221020-A1September 03, 2009Sirtris Pharmaceuticals, IncMass Spectrometry Assays for Acetyltransferase/Deacetylase Activity
    US-2009318455-A1December 24, 2009Intermune, Inc.Compounds and methods for treating inflammatory and fibrotic disorders
    US-2010035885-A1February 11, 2010President And Fellows Of Harvard College, Biomol International L.P.Compositions for manipulating the lifespan and stress response of cells and organisms
    US-2010185006-A1July 22, 2010Brigham Young UniversityNovel sirtuin activating compounds and processes for making the same
    US-2010292242-A1November 18, 2010Albany Molecular Research, Inc.Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
    US-2010292243-A1November 18, 2010Albany Molecular Research, Inc.7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
    US-2010292250-A1November 18, 2010Albany Molecular Research, Inc.CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF
    US-8017634-B2September 13, 2011President And Fellows Of Harvard College, The General Hospital CorporationCompositions for treating obesity and insulin resistance disorders
    US-8242171-B2August 14, 2012President And Fellows Of Harvard College, The General Hospital CorporationMethod for reducing the weight of a subject or inhibiting weight gain in a subject
    US-8304206-B2November 06, 2012Sirtris Pharmaceuticals, Inc.Mass spectrometry assays for identifying compounds that activate deacetylases
    US-8304413-B2November 06, 2012Intermune, Inc.Compounds and methods for treating inflammatory and fibrotic disorders
    US-8741901-B2June 03, 2014Albany Molecular Research, Inc., Bristol-Myers Squibb CompanyAryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
    US-8741936-B2June 03, 2014Intermune, Inc.Method of modulating stress-activated protein kinase system
    US-8802696-B2August 12, 2014Albany Molecular Research, Inc.7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
    US-8815894-B2August 26, 2014Bristol-Myers Squibb CompanyCrystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
    US-8841477-B2September 23, 2014Brigham Young UniversitySirtuin activating compounds and processes for making the same
    US-8846724-B2September 30, 2014President And Fellows Of Harvard College, The General Hospital CorporationCompositions for treating obesity and insulin resistance disorders
    US-8907108-B2December 09, 2014Industrial Technology Research InstituteP-type organic semiconductor material and optoelectronic device utilizing the same
    US-8969347-B2March 03, 2015Intermune, Inc.Compounds and methods for treating inflammatory and fibrotic disorders
    US-9034899-B2May 19, 2015Albany Molecular Research, Inc.Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
    US-9085531-B2July 21, 2015Albany Molecular Research, Inc., Bristol-Myers Squibb CompanyAryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
    US-9173879-B2November 03, 2015Bristol-Myers Squibb CompanyCrystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
    US-9241916-B2January 26, 2016President And Fellows Of Harvard CollegeCognitive performance with sirtuin activators
    US-9290450-B2March 22, 2016Intermune, Inc.Compounds and methods for treating inflammatory and fibrotic disorders
    US-9359379-B2June 07, 2016Intermune, Inc.Anti-fibrotic pyridinones
    US-9498476-B2November 22, 2016Albany Molecular Research, Inc.Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
    US-9499531-B2November 22, 2016Albany Molecular Research, Inc.Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
    US-9527816-B2December 27, 2016Intermune, Inc.Method of modulating stress-activated protein kinase system
    US-9597347-B2March 21, 2017President And Fellows Of Harvard College, The General Hospital CorporationCompositions for treating obesity and insulin resistance disorders
    US-9604960-B2March 28, 2017Albany Molecular Research, Inc.Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
    US-9675593-B2June 13, 2017Intermune, Inc.Anti-fibrotic pyridinones
    WO-2009082459-A2July 02, 2009Natrol, Inc.Composition anti-vieillissement contenant du resvératrol et méthode d'administration
    WO-2009082459-A3September 17, 2009Natrol, Inc.Anti-aging composition containing resveratrol and method of administration
    WO-2009126700-A1October 15, 2009Kent State UniversityHydroxylated tolans and related compounds as cosmetics or therapeutics for skin conditions
    WO-2016178713-A1November 10, 2016Flavocure Biotech LlcTherapeutic agents containing cannabis flavonoid derivatives targeting kinases, sirtuins and oncogenic agents for the treatment of cancers